In Latin America, few studies have been done in mupirocin resistance and biofilm formation in methicillin-resistant Staphylococcus aureus (MRSA). This study investigated mupirocin-resistance in MRSA isolates from pediatric patients with bacteremia and their ability to form biofilm. Antibiotic resistance was analyzed with the Kirby-Bauer test and the broth microdilution method. Bacterial biofilm formation was measured using the crystal violet assay. Among MRSA isolates, 2.3 % (5/217) exhibited a high level of mupirocin-resistance with a minimum inhibitory concentration of > 512 µg/mL, in addition to cross-resistance with clindamycin, erythromycin, gentamicin, and ciprofloxacin. Remarkably, biofilm formation in such isolates was moderate to high. This is the first report published in Argentina on clinical isolates of mupirocinresistant MRSA and it is critical for following its evolution over time at a local level and in the Latin American region.
INTRODUCTION
Common soft tissue staphylococcal infections are associated with high rates of morbidity and mortality in many countries worldwide, including Argentina. 1, 2 In particular, methicillin-resistant S. aureus (MRSA)-associated infections are lifethreatening, especially in immunocompromised hosts, because the bacteria spread from the skin to the lungs, the bloodstream or other body organs. For this reason, topical decolonization with an antimicrobial such as mupirocin is commonly done in hospitalized patients to prevent MRSA dissemination. 3 However, the effectiveness of this treatment has reduced dramatically due to the emergence of resistant strains. 4 Isolates with a low or high level of mupirocin resistance, which are defined as per the observed minimum inhibitory concentration (MIC) (8-256 μg/mL or > 512 μg/ mL, respectively), were observed. 5 Another factor contributing to the success of S. aureus as a human pathogen in health care settings is its ability to form bacterial biofilm, multicellular communities adhered onto a surface, such as medical devices or tissues. Recurrent and chronic MRSA infections associated with the development of biofilm have a great impact on treatment schedules. 6 Few studies have been done in Argentina and Latin America on the characterization of MRSA in pediatric patients. 7, 8 Likewise, much less is known on the presence of mupirocin resistance and its ability to form biofilm in MRSA. The objective of this study was to determine the presence of mupirocin-resistant MRSA (MUP-R-MRSA) and its ability to form biofilm among hospitalized patients in Hospital de Pediatría "J. P. Garrahan." 
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METHODOLOGY
This was a descriptive study with blood sample analysis using a convenient sampling strategy of patients with bacteremia between January 2011 and December 2015. Hospital Garrahan is a leading children's hospital in Argentina and a regional referral center receiving children from neighboring countries like Bolivia, Peru, and Paraguay. It is located in the Autonomous City of Buenos Aires, Argentina. The study was approved by the Institutional Review Board and the Ethics Committee of Hospital Garrahan (protocol no. 868). One blood sample was collected per patient; S. aureus was identified at the laboratory of the Department of Microbiology of Hospital Garrahan according to the Clinical and Laboratory Standards Institute (CLSI) guidelines. 9 MRSA was confirmed through the identification of specific protein profiles using a matrix-assisted laser desorption/ ionization time-of-flight (MALDI/TOF) mass spectrometry (bioMérieux, France). The antibiotic susceptibility of isolates was analyzed using the disc diffusion method for the following antibiotics: oxacillin, cefoxitin, erythromycin, clindamycin, t e i c o p l a n i n , g e n t a m i c i n , c i p r o f l o x a c i n , levofloxacin, quinupristin/dalfopristina, linezolid, minocycline, rifampicin, and trimethoprimsulfamethoxazole, as per the recommendations and the classification of the European Committee on Antimicrobial Susceptibility Testing (EUCAST). Sensitivity tests were confirmed using VITEK 2 (bioMérieux). Mupirocin susceptibility (Forberton Co. Laboratories) was analyzed using the KirbyBauer disc diffusion method, while resistance was determined by measuring the MIC. The final concentrations were determined between 0.062 and 2.048 μg/mL using the broth microdilution method. 10 Bacterial biofilm was detected using the crystal violet (CV) staining technique with culture in 96-well plates and determination of optical density (OD). Biofilm formation was estimated considering a critical OD (COD) of 0.1, corresponding to the arithmetic mean of the absorbance of negative controls plus three times the standard deviation.
11 Classification was as follows: non-biofilm-forming isolates (OD ≤ COD); weak biofilm-forming isolates (COD < OD ≤ 2 COD); moderate biofilm-forming isolates (2 COD < OD ≤ 4 COD); and strong biofilm-forming isolates (4 COD < OD). Results were described as mean ± standard deviation, and the statistical significance (p < 0.05) was determined using the InfoStat 2015 software.
RESULTS
A total of 217 clinical isolates of MRSA were analyzed; 2.3 % (5/217) were resistant to mupirocin, as determined with the Kirby-Bauer technique (Table 1 ). In addition to oxacillinand cefoxitin-resistance, clinical isolates showed moderate resistance to erythromycin, clindamycin, and gentamicin (27.6 %, 25 %, and 15.2 %, respectively) and a low resistance to ciprofloxacin, levofloxacin, trimethoprimsulfamethoxazole, and linezolid (6.9 %, 1.4 %, 0.5 %, and 0.5 %, respectively). Table 1 shows a summary of the cross- Table 1 . In addition, MUP-R-MRSA isolates were tested for their biofilm formation ability. Results showed that all MUP-R-MRSA isolates (GM-36, 42, 43, 134, and 212) formed biofilm (Figure 1) . Three of them formed a moderate amount of biofilm, whereas the other two formed strong biofilm. The analysis of the 5 mupirocin-susceptible isolates (MUP-S-MRSA) that exhibited resistance to 4-9 antibiotics (GM-4, 17, 20, 31, and 34) showed that they were also able to form biofilm at a similar level than mupirocin-resistant isolates. 
Antibiotic cross-resistance profiles and minimum inhibitory concentrations of mupirocin in methicillin-resistant Staphylococcus aureus clinical isolates
MRSA Antibiotic susceptibility
Mupirocin Oxacillin Cefoxitin Erytromycin Clindamycin Gentamicin Ciprofloxacin Levofloxacin Linezolid Rifampicin
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DISCUSSION
This study reports, for the first time in Argentina, the emergence of mupirocin resistance in MRSA among pediatric patients. Although its incidence is low (2.7 %), it is worth noting the high level of mupirocin's cross-resistance with erythromycin, clindamycin, and gentamicin. To make things even more complicated, MUP-R-MRSA isolates were able to synthesize biofilm and exhibited moderate-to-high levels of biofilm formation.
Other authors have reported a high level of simultaneous mupirocin resistance with other antibiotics in association with a more frequent MRSA colonization. [4] [5] [6] [7] [8] [9] [10] [11] [12] Therefore, mupirocin is recommended as a first-line treatment for impetigo in patients with a limited number of lesions, especially considering MRSA local resistance patterns as per the 2014 guidelines of the Infectious Diseases Society of America. 3 In a children's hospital in the USA, mupirocin resistance was detected in 14.7 % of S. aureus isolates in association with recurrent skin and soft tissue infections, which was higher than the rate observed in other community studies conducted in children (1.8 %). 4 In outpatients with skin diseases in the USA, mupirocin resistance was observed in S. aureus isolates in association with atopic dermatitis, epidermolysis bullosa, and immunosuppression as additional risk factors, with an incidence of 19.3-31.3 %. 5 It is well known that, in patients with sepsis, medical devices such as central venous lines are commonly used and may favor bacterial biofilm formation. Our findings show that all MUP-R-MRSA isolates formed biofilm. In relation to the possible correlation between mupirocin resistance in MRSA and its ability to form biofilm, other authors have reported biofilm-forming MUP-R-MRSA strains isolated in swabs from infected wounds collected after a surgery. 12 It has been suggested that biofilm formation may play a role in mupirocin resistance in the overall population of hospitalized patients.
11,12
CONCLUSION
The presence of MUP-R-MRSA clinical isolates with ability to form biofilm in hospitalized patients is an obstacle for decolonization protocols and may result in chronic or persistent infections because they are capable of surviving in the host's hostile environment. Therefore, the emergence of mupirocin resistance in MRSA isolates in Argentina is an increasing problem that calls for the future monitoring of its evolution over time. n
